髋关节镜翻修术中髋臼唇增强术的中期结局
该病例系列研究(证据等级4)评估了既往髋关节镜术后髋臼唇功能不全患者行关节镜下髋臼唇增强术的中期结局,共纳入88例患者,77例(88%)完成至少3年随访。3年和5年生存率(未转为全髋关节置换)均为93%,未再手术患者报告结局显著改善。
要点
- 关节镜下髋臼唇增强术治疗既往髋关节镜术后髋臼唇功能不全,3年和5年生存率均为93%。
- 77例完成至少3年随访的患者中,11例(14%)因持续疼痛需再次关节镜手术。
- 未再手术患者(n=61)的HOS-ADL和mHHS均显著改善,mHHS的MCID达标率78%、PASS达标率70%。
核心结论
- 关节镜下髋臼唇增强术是治疗既往髋关节镜术后髋臼唇功能不全的成功选择,患者报告结局改善且3年和5年生存率均为93%。
- 当存在有活力的自体髋臼唇组织时,该技术为处理髋臼唇病变提供了有价值的唇保留选项。
研究设计与样本
- 病例系列研究,证据等级4。
- 患者来自前瞻性收集的数据库,纳入2011年1月至2017年1月期间接受关节镜下髋臼唇增强术且至少随访3年的患者。
主要发现
- 共88例患者(39例男性,49例女性)接受翻修髋关节镜联合髋臼唇增强术,平均年龄32.8±11岁。
- 77例患者(88%)获得至少3年随访;平均随访5.2±1.2年(范围3-9年)。
- 3年和5年生存率(未转为全髋关节置换)均为93%,平均生存时间8.5年(95%CI,8.0-8.9)。
- 11例患者(14%)因持续疼痛需再次关节镜手术,再次手术距增强术平均2.6±1.4年。
- 未再手术患者(n=61)的所有患者报告结局评分显著改善,包括HOS-ADL增加20分(MCID达标率82%;PASS达标率72%)和mHHS(MCID达标率78%;PASS达标率70%)。
关键数值与推荐
- MCID和PASS基于术前与至少3年随访评分计算:HOS-ADL的MCID达标率82%、PASS达标率72%;mHHS的MCID达标率78%、PASS达标率70%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Labral augmentation has emerged as an essential procedure to address a deficient or irreparable labrum while preserving native labral tissue and restoring the hip suction seal mechanism. PURPOSE: To evaluate midterm outcomes of arthroscopic hip labral augmentation for labral insufficiency after previous hip arthroscopy. STUDY DESIGN: Case series; Level of evidence, 4. METHODS: Patients were identified from a prospectively collected database who underwent arthroscopic hip labral augmentation between January 2011 and January 2017 with a minimum 3-year follow-up. Pre- and postoperative patient-reported outcome scores were compared and included the 12-Item Short Form Health Survey physical and mental component summaries, Western Ontario and McMaster Universities Osteoarthritis Index, modified Harris Hip Score (mHHS), and Hip Outcome Score (HOS) (Activities of Daily Living [ADL] and Sport). Postoperative Tegner Activity Scale and patient satisfaction (1-10) scores were also evaluated. The minimal clinically important difference (MCID) and Patient Acceptable Symptom State (PASS) between the preoperative and minimum 3-year follow-up scores were calculated. RESULTS: A total of 88 patients (39 men, 49 women) underwent revision hip arthroscopy with labral augmentation. The average age was 32.8 ± 11 years. Of these, 77 patients (88%) were available for the minimum 3-year follow-up. The survivorship (absence of conversion to total hip arthroplasty) at 3 years and 5 years was 93% at both time points, with a mean survival time of 8.5 years (95% CI, 8.0-8.9). Eleven patients (14%) required revision arthroscopic surgery for continued pain. Revisions occurred at a mean of 2.6 ± 1.4 years after augmentation. The mean follow-up was 5.2 ± 1.2 years (range, 3-9 years). For patients not requiring subsequent surgery (n = 61), all patient-reported outcome measures significantly improved, which included a 20-point increase in HOS-ADL (MCID, 82%; PASS, 72%) and mHHS (MCID, 78%; PASS, 70%). The median postoperative Tegner score was 4 (range, 1-10). The median postoperative patient satisfaction score was 9 out of 10 (range, 1-10). CONCLUSION: Arthroscopic hip labral augmentation is a successful treatment option for patients with labral insufficiency after previous hip arthroscopy, demonstrating improved patient-reported outcomes and survivorship of 93% at 3 years and 5 years. This technique provides a valuable labral preservation option when addressing hip labral pathology when viable native labral tissue remains.
引用
- Soares RW, Ruzbarsky JJ, Arner JW, et al. Midterm Outcomes After Hip Labral Augmentation in Revision Hip Arthroscopy. Am J Sports Med. 2022. PMID: 35234524. doi:10.1177/03635465221080162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。